Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial

AIMS: In the TRITON-TIMI 38 trial, greater platelet inhibition with prasugrel reduced the first occurrence of the primary endpoint (cardiovascular death, MI, or stroke) compared with clopidogrel in patients with an acute coronary syndrome (ACS) undergoing planned percutaneous coronary intervention....

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Murphy, Sabina A., Antman, Elliott M., Wiviott, Stephen D., Weerakkody, Govinda, Morocutti, Giorgio, Huber, Kurt, Lopez-Sendon, Jose, McCabe, Carolyn H., Braunwald, Eugene
Médium: Artigo
Jazyk:Inglês
Vydáno: Oxford University Press 2008
Témata:
Clinical Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2567025/
https://ncbi.nlm.nih.gov/pubmed/18682445
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/eurheartj/ehn362
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky